Efficacy and safety of retreatment with vedolizumab in patients with ulcerative colitis

被引：0
|
作者：
Sands, B. E. [1 ]
Shafran, I. [2 ]
Farraye, F. A. [3 ]
Cheifetz, A. S. [4 ]
Abhyankar, B. [5 ]
Sankoh, S. [6 ]
Smyth, M. [7 ]
机构：
[1] Mt Sinai Hosp, Icahn Sch Med, Gastroenterol, New York, NY 10029 USA
[2] Shafran Gastroenterol Ctr, Gastroenterol, Winter Pk, FL USA
[3] Boston Med Ctr, Gastroenterol, Boston, MA USA
[4] Beth Israel Deaconess Med Ctr, Med, Boston, MA 02215 USA
[5] Takeda Global Res & Dev Ctr Europe Ltd, Clin Sci, London, England
[6] Takeda Pharmaceut Int Co, Stat, Cambridge, MA USA
[7] Takeda Global Res & Dev Ctr Europe Ltd, Med, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP028
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Retreatment With Vedolizumab in Patients With Ulcerative Colitis
    Sands, Bruce E.
    Shafran, Ira
    Farraye, Francis A.
    Cheifetz, Adam S.
    Abhyankar, Brihad
    Sankoh, Serap
    Smyth, Michael D.
    GASTROENTEROLOGY, 2015, 148 (04) : S278 - S278
  • [2] Efficacy and safety of vedolizumab in the treatment of ulcerative colitis
    Domenech, Eugeni
    Gisbert, Javier P.
    Gastroenterologia y Hepatologia, 2016, 39 (10): : 677 - 686
  • [3] Efficacy and safety of vedolizumab in the maintenance phase of ulcerative colitis
    Torralba, K. S.
    Payawal, D. A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 267 - 268
  • [4] Predictors of the efficacy of vedolizumab in patients with ulcerative colitis
    Kajikawa, Go
    Sawada, Tsunaki
    Nakamura, Masanao
    Yamamura, Takeshi
    Maeda, Keiko
    Ishikawa, Eri
    Uetsuki, Kota
    Hirose, Takashi
    Iida, Tadashi
    Mizutani, Yasuyuki
    Yamao, Kentaro
    Ishikawa, Takuya
    Furukawa, Kazuhiro
    Kawashima, Hiroki
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (03): : 407 - 421
  • [5] Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan
    Yokoyama, Koji
    Yamamoto, Yoko
    Nambu, Ryusuke
    Hagiwara, Shin-Ichiro
    Abukawa, Daiki
    Mizuochi, Tatsuki
    Kudo, Takahiro
    Sado, Tomomitsu
    Iwata, Naomi
    Ishige, Takashi
    Iwama, Itaru
    Kumagai, Hideki
    Arai, Katsuhiro
    Shimizu, Toshiaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (07) : 1107 - 1115
  • [6] Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
    Sandborn, William J.
    Baert, Filip
    Danese, Silvio
    Krznaric, Zeljko
    Kobayashi, Taku
    Yao, Xiaopan
    Chen, Jingjing
    Rosario, Maria
    Bhatia, Siddharth
    Kisfalvi, Krisztina
    D'Haens, Geert
    Vermeire, Severine
    GASTROENTEROLOGY, 2020, 158 (03) : 562 - +
  • [7] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
    Yajnik, Vijay
    Khan, Nabeel
    Dubinsky, Marla
    Axler, Jeffrey
    James, Alexandra
    Abhyankar, Brihad
    Lasch, Karen
    ADVANCES IN THERAPY, 2017, 34 (02) : 542 - 559
  • [8] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
    Vijay Yajnik
    Nabeel Khan
    Marla Dubinsky
    Jeffrey Axler
    Alexandra James
    Brihad Abhyankar
    Karen Lasch
    Advances in Therapy, 2017, 34 : 542 - 559
  • [9] Efficacy and safety of retreatment with vedolizumab in patients with Crohn's disease
    Sands, B. E.
    Shafran, I.
    Farraye, F. A.
    Cheifetz, A. S.
    Abhyankar, B.
    Sankoh, S.
    Smyth, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S377 - S378
  • [10] The safety of vedolizumab for the treatment of ulcerative colitis
    Novak, Gregor
    Hindryckx, Pieter
    Khanna, Reena
    Jairath, Vipul
    Feagan, Brian G.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 501 - 507
12345